PT - JOURNAL ARTICLE AU - Selewski, D.T. AU - Shah, G.V. AU - Segal, B.M. AU - Rajdev, P.A. AU - Mukherji, S.K. TI - Natalizumab (Tysabri) AID - 10.3174/ajnr.A2226 DP - 2010 Oct 01 TA - American Journal of Neuroradiology PG - 1588--1590 VI - 31 IP - 9 4099 - http://www.ajnr.org/content/31/9/1588.short 4100 - http://www.ajnr.org/content/31/9/1588.full SO - Am. J. Neuroradiol.2010 Oct 01; 31 AB - SUMMARY: Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent. FDAUS Food and Drug AdministrationFLAIRfluid-attenuated inversion recoveryFSEfast spin-echoIgGimmunoglobulin GMAdCAM-1mucosal adressin cell adhesion moleculeMSmultiple sclerosisPMLprogressive multifocal leukoencephalopathyTOUCHTysabri Outreach Unified Commitment to HealthVCAM -1vascular cell adhesion molecule-1